参考文献

[1] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66 (2): 115-132.

[2] NATIONAL CANCER INSTITUTE. Cancer Stat Facts: Female Breast Cancer[OL]. SEER Cancer Statistics Review, 2018. https://seer.cancer.gov/statfacts/html/breast.html.

[3] FIDLER M M, GUPTA S, SOERJOMATARAM I, et al. Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study[J].Lancet Oncol, 2017, 18 (12): 1579-1589.

[4] NOONE A M, HOWLADER N, KRAPCHO M, et al. SEER Cancer Statistics Review, 1975-2015[C]. National Cancer Institute, Bethesda, September 10, 2018.

[5] National Cancer Institute. Cancer Stat Facts: Female Breast Cancer [OL]. SEER Cancer Statistics Review, 2018. https://seer.cancer.gov/statfacts/html/breast.html.

[6] WARNER E. Breast-Cancer Screening[J]. N Engl J Med, 2011, 365:1025-1032.

[7] LOCONTE N K, BREWSTER A M, KAUR J S, et al. Alcohol and Cancer: A Statement of the American Society of Clinical Oncology[J]. J Clin Oncol, 2017, 36 (1): JCO2017761155.

[8] ISLAMI F, GODING SAUER A, MILLER K D, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States[J].CA Cancer J Clin, 2017, 68 (1):31.

[9] LOWRY S J, KAPPHAHN K, CHLEBOWSKI R, et al. Alcohol Use and Breast Cancer Survival among Participants in the Women's Health Initiative[J]. Cancer Epidemiology Biomarkers & Prevention, 2016, 25 (8): 1268.

[10] REEVES G K, PIRIE K, BERAL V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study[J]. BMJ, 2007, 335(7630):1134.

[11] FU L, KETTNER N M. The Circadian Clock in Cancer Development and Therapy[J]. Prog Mol Biol Transl Sci, 2013, 119: 221-282.

[12] STRAIF K, BAAN R, GROSSE Y, et al. Carcinogenicity of shift-work, painting, and fire-fighting[J]. Lancet Oncol, 2007, 8 (12): 1065-1066.

[13] AUNE D, VIEIRA A R, ROSENBLATT D A N, et al. Fruits, vegetables and breast cancer risk: a systematic review and meta-analysis of prospective studies[J]. Breast Cancer Res Treat, 2012, 134 (2): 479-493.

[14] CHEN M, RAO Y, ZHENG Y, et al. Association between soy isoflavone intake and breast cancer risk for pre- and post-menopausal women: a meta-analysis of epidemiological studies[J]. PloS one, 2014, 9 (2): e89288.

[15] WADA K, NAKAMURAK, TAMAI Y, et al. Soy isoflavone intake and breast cancer risk in Japan: from the Takayama study[J]. Int J Cancer, 2013, 133 (4): 952-960.

[16] MOUTSATSOU P, PAPOUTSI Z, KASSI E, et al. Fatty acids derived from royal jelly are modulators of estrogen receptor functions[J]. PloS one, 2010, 5 (12): e15594.

[17] GEORGIEV D B, METKA M, HUBERJ C, et al. Effects of an herbal medication containing bee products on menopausal symptoms and cardiovascular risk markers: results of a pilot open-uncontrolled trial[J]. Med Gen Med, 2004, 6 (4): 46.

[18] GRUBE B J, ENG E T, KAO Y C, et al. White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation[J]. Journal of nutrition, 2001, 131(12):3288-3293.

[19] SHIN A, KIM J, LIM SY, et al. Dietary mushroom intake and the risk of breast cancer based on hormone receptor status[J]. Nutrition and cancer, 2010, 62 (4): 476-483.

[20] BURKMAN R, SCHLESSELMAN J J, ZIEMAN M. Safety concerns and health benefits associated with oral contraception[J]. American Journal of Obstetrics and Gynecology, 2004, 190(4 Suppl):S5-22.

[21] BASSUK S S, MANSON J E. Oral contraceptives and menopausal hormone therapy:relative and attributable risks of cardiovascular disease, cancer, and other health outcomes[J].Annals of Epidemiology, 2015, 25(3):193-200.

[22] WENTZENSEN N, BERRINGTON D G A. The Pill's gestation: from birth control to cancer prevention[J]. Lancet Oncology, 2015, 16(9):1004-1006.

[23] Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53, 297 women with breast cancer and 100, 239 women without breast cancer from 54 epidemiological studies[J].Lancet, 1996, 347(9017):1713-1727.

[24] HUNTER D J . COLDITZ G A, HANKINSON S E. Oral contraceptive use and breast cancer: a prospective study of young women[J]. Cancer Epidemiology Biomarkers and Prevention, 2010, 19 (10):2496-2502.

[25] MICHELS K A, PFEIFFER R M, BRINTON L A, et al. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers[J]. JAMA Oncology, 2018.

[26] HAVRILESKY L J, et al. Oral contraceptive pills as primary prevention for ovarian cancer:a systematic review and meta-analysis[J]. Obstetrics and Gynecology, 2013, 122(1):139-147.

[27] MURPHY N, XU L, ZERVOUDAKIS A, et al. Reproductive and menstrual factors and colorectal cancer incidence in the Women's Health Initiative Observational Study[J]. British Journal of Cancer, 2017, 116(1):117-125.

[28] Breastcancer. org. Genetics[OL]. http://www.breastcancer.org/risk/factors/genetics.

[29] ROBSON M, IM S A, SENKUS E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation[J]. New England Journal of Medicine, 2017, 377 (6): 523.

[30] MCCABE N, TURNER N C, LORD C J, et al. Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly (ADP-Ribose) Polymerase Inhibition[J].Cancer Res, 2006, 66 (16): 8109-8115.

[31] U. S. Preventive Services Task Force. Archived: Breast Cancer: Screening[OL]. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/breast-cancer-screening.

[32] HOOLEY R J, DURAND M A, PHILPOTTS L E. et al.， Advances in Digital Breast Tomosynthesis[J]. American Journal of Roentgenology, 2017; 208: 256-266.

[33] DUPONT W D, PAGE D L, PARL F F, et al.Long-Term Risk of Breast Cancer in Women with Fibroadenoma[J]. N Engl J Med. 1994 Jul 7;331(1):10-15.

[34] CARTER C L, CORLE D K, MICOZZI M S, et al.A prospective study of the development of breast cancer in 16, 692 women with a benign tumor in the breast[J]. Am J Epidemiol 1988;128:467-477.

[35] LEVI F, RANDIMBISON L, TE V C, et al.Incidence of breast cancer in women with fibroadenoma[J]. Int J Cancer, 1994, 57(5):681-683.

[36] CARTER B A, PAGE D L, SCHUYLER P, et al.No elevation in long-term breast carcinoma risk for women with fibroadenomas that contain atypical hyperplasia[J]. Cancer, 2001, 92(1):30-36.

[37] SONNENBLICK A, FRANCIS P A, AZIM H A, et al. Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer [J]. European Journal of Cancer, 1990, 51 (12): 1481-1489.

[38] YERUSHALMI R, WOODS R, RAVDIN P M. Ki67 in breast cancer: prognostic and predictive potential [J]. The Lancet. Oncology, 2010, 11 (2): 174-183.

[39] FINN R S, MARTIN M, RUGO H S, et al. Palbociclib and Letrozole in Advanced Breast Cancer[J]. N Engl J Med, 2016, 375:1925-1936.

[40] TURNER N C, RO J, ANDR F, et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer[J]. N Engl J Med, 2015, 373:209-219.

[41] DICKSON M A, SCHWARTZ G K, KEOHAN M L, et al. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib[J]. AMA Oncol, 2016, 2 (7): 937-940.

[42] SLAMON D J, LEYLAND-JONES B, SHAK S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J].N Engl J Med, 2001, 344 (11): 783-792.

[43] SLAMON D, EIERMANN W, ROBERT N, et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer[J]. The New England Journal of Medicine, 2011, 365(14):1273-1283.

[44] MA F, LI Q, CHEN S S, et al. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer[J]. J Clin Oncol, 2017, 35 (27): 3105-3112.

[45] ROBSON M, IM SA, SENKUS E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation[J]. N Engl J Med, 2017, 377:523-533.

[46] LITTON J K, RUGO H S, ETTL J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation[J]. N Engl J Med, 2018, 379:753-763.

[47] WANG W, ERBE A K, HANK J A, et al. NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy[J]. Frontiers in Immunology, 2015, 6:368.

[48] BOERO S, MORABITO A, BANELLI B, et al. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines[J]. Journal of Translational Medicine, 2015, 13:324.

[49] ADAMS S, SCHMID P, RUGO H S, et al. Phase 2 study of pembrolizumab (pembro)monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC):KEYNOTE-086 cohort A[J]. J Clin Oncol, 2017, 35 (suppl; abstr 1008).

[50] SCHMID P, CRUZ C, BRAITEH F S, et al: Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analysis[C]. 2017 AACR Annual Meeting, Washington, DC. 2017, 4. Abstract 2986.

[51] TOLANEY S, SAVULSKY C, AKTAN G, et al. Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer[C]. 2016 San Antonio Breast Cancer Symposium; San Antonio, TX. 2016, 12. Abstract P5-15-02.

[52] ROSENBERG S A, PACKARD B S, AEBERSOLD P M, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma.A preliminary report[J]. N Engl J Med, 1988, 319:1676-1680.

[53] YANG J C, ROSENBERG S A. Adoptive T-Cell Therapy for Cancer[J]. Adv Immunol, 2016, 130:279-294.

[54] ZACHARAKIS N, CHINNASAMY H, BLACK M, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer[J]. Nat Med.2018, 24(6):724-730.

[55] PDQ ^® Adult Treatment Editorial Board. PDQ Breast Cancer Treatment During Pregnancy[C]. National Cancer Institute, Bethesda, September 4, 2018.

[56] JOHNSON S B, PARK H S, GROSS C P, et al. Use of Alternative Medicine for Cancer and Its Impact on Survival[J]. J Natl Cancer Inst, 2018, 110 (1): E401. uShtXtEWnHHQTs8suAkAI18YG9x2IwhUEsNRkdOqJ2m8BZbXaSt6xLkmslxPwjMR